Q-omics provides the consensus-scored ETV3L profile across patient tissues and cancer cell-line models. ETV3L expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ETV3L is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, ETV3L RNA expression shows 7,817 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ETV3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETV3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETV3L survival associations across molecular data types. ETV3L RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETV3L RNA expression–survival associations across cancer types. High ETV3L expression shows unfavorable associations in KIRC and LIHC, but favorable associations in HNSC, ESCA, SCLC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ETV3L RNA expression.
This table summarizes ETV3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ETV3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETV3L shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, LIHC, LUSC and CHOL. The HNSC box plot shows higher ETV3L RNA expression in tumor versus normal tissue (log2 FC = +0.190, t-test p = .001).
This table shows molecular features associated with ETV3L in patient tissues and cancer cell lines. In patient samples, ETV3L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ETV3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
